Predicting How Ulcerative Colitis Patients Respond to Treatments
Develops a model predicting response to vedolizumab, ustekinumab or tofacitinib in ulcerative colitis.
Key facts
- Who runs it
- Asan Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Prediction Model for Response to Biologics and Small Molecular Agent for UC
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 5 Feb 2022
- Expected to end
- 31 Dec 2026
- Type of study
- Observational
- Treatments tested
- Vedolizumab, Ustekinumab, or Tofacitinib
- Record updated
- 15 February 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Korean adults with ulcerative colitis who are going to start vedolizumab, ustekinumab, or tofacitinib. It will build a model to predict who responds to these drugs.
- Age
- 18 to 79 years
- Sex
- All sexes can join.
- Disease stage
- Ulcerative colitis confirmed by symptoms, endoscopy and tissue (biopsy) findings.
- Earlier treatment
- The person is going to receive vedolizumab, ustekinumab, or tofacitinib. Having had the colon removed because of ulcerative colitis rules a person out.
Main reasons for not taking part
- Not Korean ethnicity by family history
- Inflammatory bowel disease that cannot be classified
- Colon removed (colectomy) because of ulcerative colitis
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Who cannot take part
- Patients who already received colectomy due to ulcerative colitis
- Inflammatory Bowel Disease Unclassified
- Not Korean ethnicity by family history
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 79 years old?
Where in South Korea
- Asan Medical CenterSeoul, South KoreaContact: Byong Duk Ye, MD, PhDTaking people
About the trial
What the trial wants to find out
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
The group in the trial
- Patients with confirmed ulcerative colitis
Patients with confirmed ulcerative colitis, who are going to receive vedolizumab therapy (n=100: development cohort n=70 and validation cohort n=30), ustekinumab therapy (n=100: development cohort n=70 and validation cohort n=30), or tofacitinib therapy (n=100: development cohort n=70 and validation cohort n=30), will be enrolled.
Treatment: Vedolizumab, Ustekinumab, or Tofacitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Establishment of Prediction Model of Biologics and Small Molecular Agent for Patients With Ulcerative Colitis Using Longitudinal Data
- Plain-language title
- Predicting How Ulcerative Colitis Patients Respond to TreatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT05186623, who can take part
- Record updated
- 15 February 2022